INmune Bio, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference and the Baird Global Healthcare Conference
07 sept. 2022 09h00 HE
|
INmune Bio, Inc.
Boca Raton, FL, Sept. 07, 2022 (GLOBE NEWSWIRE) -- INmune Bio (NASDAQ: INMB), a clinical- stage immunology company focused on developing treatments that harness the patient’s immune system to fight...
Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome in Patients Receiving CAR T Cell Therapy
06 sept. 2022 08h00 HE
|
Enlivex Therapeutics Ltd
Nes-Ziona, Israel, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased...
Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment Conference
06 sept. 2022 08h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that management will participate virtually in the hybrid in-person and virtual H.C. Wainwright 24th...
Enlivex Announces Regulatory Clearance in Multiple Countries for Integration of Frozen Allocetra Formulation and Expansion of Patient Population in its Sepsis Phase II Clinical Trial
24 août 2022 08h00 HE
|
Enlivex Therapeutics Ltd
Sepsis Phase II protocol amendments have been cleared by regulatory authorities in Israel, Spain, and Greece. In addition to these clearances, Enlivex plans to obtain clearances for these protocol...
SciSparc Ltd. Announces Additional Positive Results for the Cocaine Addiction Treatment of its Psychedelic-based Pharma Collaboration with Clearmind Medicine Inc.
24 août 2022 07h30 HE
|
SciSparc Ltd
Results indicate significant decrease in cocaine craving in a sub-group that received the treatment TEL AVIV, Israel, Aug. 24, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a...
Enlivex Announces Second Quarter 2022 Financial Results and Provides a Business Update
22 août 2022 08h00 HE
|
Enlivex Therapeutics Ltd
Dosed first patient in Phase I/II trial evaluating Allocetra™ combined with chemotherapy in patients with peritoneal metastases arising from solid cancersReceived Israeli Ministry of Health approval...
Scisparc Announces the Full Exercise of Pre-Funded Warrants
19 août 2022 06h45 HE
|
SciSparc Ltd
The pre-funded warrants were issued as part of the $10 million private placement from June 2022 TEL AVIV, Israel, Aug. 19, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or...
SciSparc will Deposit $1 million in Escrow for its Intention to Enter Into an Agreement to Acquire American Food Supplements and Cosmetics Brand
18 août 2022 08h15 HE
|
SciSparc Ltd
The Company has signed an escrow agreement following the signing of a non-binding letter of intent and will be deposit a $1.0 million as an initial intention to enter into a definitive acquisition...
Enlivex Receives Israeli Ministry of Health Approval for the Initiation of a Phase I/II Trial Evaluating Allocetra™ Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors
17 août 2022 08h00 HE
|
Enlivex Therapeutics Ltd
Trial builds on encouraging preclinical studies conducted in collaboration with Yale Cancer Center that showed a substantial, statistically significant survival benefit when Allocetra™ was combined...
SciSparc Signs a Non- Binding Letter of Intent to Acquire American Food Supplements and Cosmetics Brand in Approximately $20 Million Deal
15 août 2022 08h30 HE
|
SciSparc Ltd
The Letter of Intent contemplates the purchasing of a brand, trademark and Amazon.com seller account, a management agreement, a U.S. distribution agreement and an option to expand to new territories ...